{"id":715510,"date":"2020-10-21T17:30:00","date_gmt":"2020-10-21T17:30:00","guid":{"rendered":"https:\/\/www.pm360online.com\/?guid=a4d44f877d19c4ec98445e260a520a7a"},"modified":"2020-10-21T17:30:00","modified_gmt":"2020-10-21T17:30:00","slug":"onxeo-announces-enrollment-of-first-patient-in-phase-ib-ii-study-revocan","status":"publish","type":"post","link":"https:\/\/www.pm360online.com\/onxeo-announces-enrollment-of-first-patient-in-phase-ib-ii-study-revocan\/","title":{"rendered":"Onxeo Announces Enrollment of First Patient in Phase Ib\/II Study Revocan"},"content":{"rendered":"<p><![CDATA[PARIS, Oct.  21, 2020  (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (\u201cOnxeo\u201d or \u201cthe Company\u201d), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), in particular against rare or resistant cancers, today announced a new milestone in the clinical development of AsiDNA\u2122 with the treatment of the first patient in the Revocan1 phase 1b\/2 study designed to evaluate the effect of AsiDNA\u2122, Onxeo\u2019s first-in-class DDR inhibitor, on the acquired resistance to PARP inhibitor (PARPi) niraparib for second line maintenance treatment of relapsed ovarian cancer. First results from this study are expected in early 2021.]]><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":74553,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[71350,71360],"tags":[],"_links":{"self":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts\/715510"}],"collection":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/users\/74553"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/comments?post=715510"}],"version-history":[{"count":0,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts\/715510\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/media?parent=715510"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/categories?post=715510"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/tags?post=715510"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}